|
Compound class:
Antibody
Comment: CMTX-101 is a humanized monoclonal antibody against members of the DNABII family of bacterial DNA-binding proteins [1]. It disrupts bacterial biofilms and is being developed by Clarametyx Biosciences (Ohio, USA) as an immune-mediated therapy for serious infections associated with biofilms.
|
| No information available. |
Summary of Clinical Use  |
| CMTX-101 is being developed as an adjunct therapy with standard of care antibacterials, for the treatment of Pseudomonas aeuriginosa lung infections in patients with cystic fibrosis. It has progressed to the Phase 2a portion of NCT06159725, with initial findings expected in 2025. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06159725 | A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis | Phase 1/Phase 2 Interventional | Clarametyx Biosciences, Inc. | ||
